Literature DB >> 15172261

Bilateral versus single internal thoracic artery grafting in oral-treated diabetic subsets: comparative seven-year outcome analysis.

Oren Lev-Ran1, Rony Braunstein, Nahum Nesher, Yanai Ben-Gal, Gil Bolotin, Gideon Uretzky.   

Abstract

BACKGROUND: Recent interest has focused on the use of arterial conduits in diabetic subsets. To date, the long-term benefits of bilateral internal thoracic artery (BITA) grafting in this subgroup remain in question.
METHODS: Two hundred eighty-five consecutive oral-treated diabetics operated on nonemergent basis (1996 to 1998) were compared according to the surgical technique, left-sided skeletonized BITA (n = 228) or single internal thoracic artery- saphenous veins (SITA) (n = 57). Patients with chronic lung disease, usually preselected to SITA grafting, were not included.
RESULTS: The respective grafts to patient ratio was 3.1 +/- 1 and 3.2 +/- 0.8 for the SITA and BITA groups (p = NS). Complementary conduits used in the BITA group were gastroepiploic arteries (25%) and saphenous veins (13%). Early outcome was comparable, including the incidence of deep sternal infections (1.8% in both groups). During follow-up (range, 4 to 7.5 years; median, 5), there were less repeat revascularizations (4.4% vs 12.3%, p = 0.025) and major adverse cardiac events (MACE) (11.2% vs 36.8%, p < 0.0001) in the BITA group. At 7 years, survival (Kaplan-Meier) (75% vs 59%, p = 0.006, log-rank), freedom from cardiac mortality (92% vs 68%, p < 0.0001), and freedom from MACE (70% vs 59%, p = 0.004) were superior in the BITA group. Multivariate analysis identified the use of BITA as a protective factor against the occurrence of late cardiac mortality (odds ratio [OR] 0.2) and MACE (OR 0.3); conversely, SITA-saphenous vein arrangements increased the risk by fivefold (OR 5, confidence interval limits [CL] 1.6 to 16.6, p = 0.005) and threefold (OR 3.3, CL 1.5 to 9, p = 0.005), respectively.
CONCLUSIONS: Left-sided BITA grafting confers improved long-term survival and event-free survival in oral-treated diabetics. We, therefore, recommended this approach in this diabetic subset.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172261     DOI: 10.1016/j.athoracsur.2003.12.061

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Anaortic total arterial OPCAB - Panacea to all ills?

Authors:  O P Yadava
Journal:  Indian Heart J       Date:  2015-06-13

2.  [Experiences collected in more than 2,300 diabetics undergoing coronary artery bypass grafting: patients with a specific risk profile].

Authors:  A H Lauruschkat; A Albert; B Arnrich; S Bauer; F Dalladaku; I C Ennker; U Rosendahl; J Ennker
Journal:  Clin Res Cardiol       Date:  2006-01       Impact factor: 5.460

3.  Analysis of transit time flow of the right internal thoracic artery anastomosed to the left anterior descending artery compared to the left internal thoracic artery.

Authors:  Rodrigo Milani; Daniela de Moraes; Aline Sanches; Rodrigo Jardim; Thais Lumikoski; Gabriela Miotto; Vitor Hugo Santana; Paulo Roberto Brofman
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

4.  Sterile Necrosis of the Sternum: A Rare Complication Following Coronary Artery Bypass Surgery.

Authors:  Emmanouel Papadakis; Maria Kalliopi Konstantinidou; Meletios A Kanakis
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2017-12-05

Review 5.  Effect of bilateral internal thoracic artery harvesting on deep sternal wound infection in diabetic patients: Review of literature.

Authors:  Matiullah Masroor; Xianming Fu; Umar Zeb Khan; Yuan Zhao
Journal:  Ann Med Surg (Lond)       Date:  2021-05-07

6.  Improving long term outcome for diabetic patients undergoing surgical revascularization by use of the radial artery conduit: a propensity matched study.

Authors:  Darryl M Hoffman; Kamellia R Dimitrova; Helbert Decastro; Patricia Friedmann; Charles M Geller; Wilson Ko; Robert F Tranbaugh
Journal:  J Cardiothorac Surg       Date:  2013-02-19       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.